Related Experiment Videos
Neopterin in patients with choroidal melanoma
H Gerding1, G Cremer-Bartels, K Krause
1Dept. of Ophthalmology, University of Münster, Germany.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies
|April 1, 1993
Summary
Neopterin levels in urine and serum were studied in patients with malignant melanoma of the choroid. Elevated neopterin may indicate poor prognosis and aid in monitoring disease progression.
Area of Science:
- Ophthalmology
- Immunology
- Oncology
Background:
- Malignant melanoma of the choroid is a rare but serious ocular tumor.
- Biomarkers are needed for prognostic assessment and monitoring of choroidal melanoma.
- Neopterin is a marker of immune system activation.
Purpose of the Study:
- To investigate the utility of neopterin as a prognostic marker in patients with malignant choroidal melanoma.
- To compare neopterin levels in melanoma patients with healthy controls.
Main Methods:
- Neopterin concentrations in serum and urine were measured in 101 patients with choroidal melanoma and healthy volunteers.
- Patients included those with untreated, treated, and regressed melanomas, mostly stage I-III.
- Follow-up was conducted for at least 14 months to assess clinical events.
Main Results:
- 16% of melanoma patients exhibited elevated serum and urine neopterin levels compared to controls.
- Patients experiencing critical events like orbital infiltration or metastatic disease showed higher neopterin concentrations.
- One patient with metastatic disease had extremely high neopterin levels.
Conclusions:
- Neopterin levels may serve as an informative prognostic factor for patients with malignant choroidal melanoma.
- Monitoring neopterin could aid in predicting disease progression and outcomes.
- Further research is warranted to validate neopterin's role in managing choroidal melanoma.